Melanoma and Skin Cancer Highlights From ASCO 2022

Jeffrey S. Weber, MD, PhD


June 27, 2022

Key studies on melanoma and skin cancers presented at ASCO 2022 included refinements to neoaduvant therapies for melanoma and two promising agents in advanced disease, one in melanoma and one in Merkel cell carcinoma.

Dr Jeffrey Weber, of NYU Langone's Perlmutter Cancer Center, reports first on neoadjuvant studies in melanoma. He reviews survival data from the phase 2 PRADO trial, a study of personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in stage III melanoma. The study found that patients with partial pathologic responses had worse outcomes, suggesting that they might benefit from adjuvant systemic therapy.

Other neoaduvant studies discussed include the Neo Trio trial of pembrolizumab alone or in combination with dabrafenib + trametinib in resectable BRAF-mutated stage III melanoma, and neoaduvant PD-1 blockade in resectable desmoplastic melanoma.

In advanced disease, Dr Weber reviews data presented on two new therapies. He discusses a phase 2 trial of camrelizumab, an IgG4 antibody against PD-1, combined with apatinib and temozolomide for patients with advanced acral melanoma. He closes with a report examining navtemadlin, an oral small-molecule inhibitor of MDM2 in metastatic Merkel cell carcinoma.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.